{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T18:28:05Z","timestamp":1769797685756,"version":"3.49.0"},"reference-count":38,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016016","name":"Gilead Sciences, S.L.U.","doi-asserted-by":"publisher","award":["IN-ES-980-6335"],"award-info":[{"award-number":["IN-ES-980-6335"]}],"id":[{"id":"10.13039\/100016016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"crossref","award":["PI19\/01360"],"award-info":[{"award-number":["PI19\/01360"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"crossref","award":["PI23\/0008"],"award-info":[{"award-number":["PI23\/0008"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"crossref","award":["INT24\/00021"],"award-info":[{"award-number":["INT24\/00021"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003359","name":"Generalitat Valenciana","doi-asserted-by":"crossref","award":["AICO\/2021\/035"],"award-info":[{"award-number":["AICO\/2021\/035"]}],"id":[{"id":"10.13039\/501100003359","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003359","name":"Generalitat Valenciana","doi-asserted-by":"crossref","award":["CIPROM\/2023\/16"],"award-info":[{"award-number":["CIPROM\/2023\/16"]}],"id":[{"id":"10.13039\/501100003359","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100015755","name":"CIBER\u2014Consorcio Centro de Investigaci\u00f3n Biom\u00e9dicaen Red","doi-asserted-by":"publisher","award":["CB06\/04\/0065"],"award-info":[{"award-number":["CB06\/04\/0065"]}],"id":[{"id":"10.13039\/501100015755","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Background and Aims: Changes in hepatitis delta virus (HDV) epidemiology have been highlighted recently in the context of increasing worldwide migrations. The lack of comprehensive real-world data on HDV in the Valencia region highlights the need for a structured registry to accurately estimate disease prevalence and burden and to generate robust real-world evidence on clinical outcomes and therapeutic effectiveness. We aimed to better understand the barriers for successful HDV patient care in our region by establishing a registry as well as linking previously under-recognized or lost to follow-up (FU)cases to care. Methods: After a search of all possible HDV cases in a Spanish region, attempts were made (through letters and phone calls) to relink to care those lost to FU. Two approaches were undertaken: (i) search of the Microbiology Labs Database, and (ii) clinical chart review from adult patients attending the Hepatology or Infectious Disease (ID) Units outpatient clinics of the three participant hospitals between January 2011 and June 2021. Results: Only one third of anti-HDV positive patients without adequate clinical management could be successfully linked or re-linked to care, highlighting a substantial gap in follow-up. Among 243 HDV cases detected (7.5% of HBsAg-positive patients), 111 belonged to the hospitals\u2019 health department, and after excluding deceased or transplanted individuals, the final study cohort consisted of 84 patients. Of these, 27.4% were adequately followed in Hepatology or Infectious Disease Clinics, 11.9% had been inadequately followed recently, 45.2% had been lost to follow-up for several years, and 15.5% had never been evaluated in outpatient clinics. Overall, only a third of the patients without adequate clinical management could be successfully linked\/relinked to care. Conclusions: In our setting, only a minority of anti-HDV positive patients are adequately managed in specialized outpatient clinics, with unsuccessful attempts to link many patients to care, particularly among young migrant men. These findings underscore the need for alternative strategies, such as decentralized testing, reflex testing, and the involvement of patient navigators or social workers, to strengthen linkage to care and improve retention.<\/jats:p>","DOI":"10.3390\/v18020174","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T15:04:46Z","timestamp":1769612686000},"page":"174","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Suboptimal Linkage to Care of Delta-Infected Patients in an Area with Increasing Migration-Driven Prevalence of Hepatitis D in Recent Years"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5424-3479","authenticated-orcid":false,"given":"\u00c2ngela","family":"Carvalho-Gomes","sequence":"first","affiliation":[{"name":"Hepatology, Hepatobiliopancreatic Surgery and Transplant Group, La Fe Health Research Institute (IIS La Fe), 46026 Valencia, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBERehd), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariadna","family":"Bono","sequence":"additional","affiliation":[{"name":"Hepatology, Hepatobiliopancreatic Surgery and Transplant Group, La Fe Health Research Institute (IIS La Fe), 46026 Valencia, Spain"},{"name":"Hepatology Unit, Department of Gastroenterology, La Fe University Hospital, 46026 Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6960-078X","authenticated-orcid":false,"given":"Lola","family":"G\u00f3mez","sequence":"additional","affiliation":[{"name":"Department of Microbiology, La Fe University and Polytechnic Hospital, 46026 Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susana","family":"Sabater","sequence":"additional","affiliation":[{"name":"Castell\u00f3n General University Hospital, 12004 Castell\u00f3n, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8007-5739","authenticated-orcid":false,"given":"Juan Carlos","family":"Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Dr. Balmis General University Hospital, 03010 Alicante, Spain"},{"name":"Alicante Institute for Health and Biomedical Research (ISABIAL), 03010 Alicante, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Palau","sequence":"additional","affiliation":[{"name":"Castell\u00f3n General University Hospital, 12004 Castell\u00f3n, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"For\u00e9s","sequence":"additional","affiliation":[{"name":"Castell\u00f3n General University Hospital, 12004 Castell\u00f3n, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5555-6418","authenticated-orcid":false,"given":"Mar\u00eda","family":"Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Dr. Balmis General University Hospital, 03010 Alicante, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"Pascual","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBERehd), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain"},{"name":"Dr. Balmis General University Hospital, 03010 Alicante, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8803-3963","authenticated-orcid":false,"given":"Maria \u00c0ngels","family":"Cebri\u00e0 i Iranzo","sequence":"additional","affiliation":[{"name":"Hepatology, Hepatobiliopancreatic Surgery and Transplant Group, La Fe Health Research Institute (IIS La Fe), 46026 Valencia, Spain"},{"name":"Physiotherapy Department, University of Valencia, 46010 Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mart\u00edn","family":"Prieto","sequence":"additional","affiliation":[{"name":"Hepatology, Hepatobiliopancreatic Surgery and Transplant Group, La Fe Health Research Institute (IIS La Fe), 46026 Valencia, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBERehd), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9246-4264","authenticated-orcid":false,"given":"Marina","family":"Berenguer","sequence":"additional","affiliation":[{"name":"Hepatology, Hepatobiliopancreatic Surgery and Transplant Group, La Fe Health Research Institute (IIS La Fe), 46026 Valencia, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBERehd), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain"},{"name":"Hepatology Unit, Department of Gastroenterology, La Fe University Hospital, 46026 Valencia, Spain"},{"name":"Medicine Department, University of Valencia, 46010 Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1093\/infdis\/jiz633","article-title":"Estimating the global prevalence, disease progression, and clinical outcome of hepatitis delta virus infection","volume":"221","author":"Miao","year":"2020","journal-title":"J. Infect. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jhep.2020.04.008","article-title":"The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis","volume":"73","author":"Stockdale","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1053\/j.gastro.2018.09.058","article-title":"Pathogenesis of and New Therapies for Hepatitis D","volume":"156","author":"Koh","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jhep.2020.02.030","article-title":"Chronic hepatitis D and hepatocellular carcinoma: A systematic review and meta-analysis of observational studies","volume":"73","author":"Alfaiate","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","author":"Lampertico","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/jmv.1890260312","article-title":"Epidemiology of delta infection in Spain","volume":"26","author":"Buti","year":"1988","journal-title":"J. Med. Virol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1473-3099(18)30663-7","article-title":"Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): A randomised, placebo controlled, phase 2 trial","volume":"19","author":"Wedemeyer","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa0912696","article-title":"Peginterferon plus Adefovir versus Either Drug Alone for Hepatitis Delta","volume":"364","author":"Wedemeyer","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jhep.2016.04.016","article-title":"Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib\/IIa study","volume":"65","author":"Bogomolov","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1473-3099(22)00318-8","article-title":"Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): A multicentre, randomised, parallel-group, open-label, phase 2 trial","volume":"23","author":"Wedemeyer","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"106311","DOI":"10.1016\/j.antiviral.2025.106311","article-title":"Bulevirtide for chronic hepatitis delta: From clinical trials to real life data: An expert opinion report","volume":"245","author":"Asselah","year":"2025","journal-title":"Antivir. Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.cld.2019.04.005","article-title":"HBV\/HDV Coinfection: A Challenge for Therapeutics","volume":"23","author":"Koh","year":"2019","journal-title":"Clin. Liver Dis."},{"key":"ref_13","unstructured":"European Medicines Agency (EMA) (2025, January 02). Hepcludex|European Medicines Agency (EMA), Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/hepcludex."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jhep.2023.05.001","article-title":"EASL Clinical Practice Guidelines on hepatitis delta virus","volume":"79","author":"Brunetto","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"100547","DOI":"10.1016\/j.jhepr.2022.100547","article-title":"Implementation of anti-HDV reflex testing among HBsAg-positive individuals increases testing for hepatitis D","volume":"4","author":"Palom","year":"2022","journal-title":"JHEP Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1111\/liv.15776","article-title":"Impact of hepatitis D reflex testing on the future disease burden: A modelling analysis","volume":"43","author":"Buti","year":"2023","journal-title":"Liver Int."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.jhep.2023.06.002","article-title":"Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: Report from the 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference","volume":"79","author":"Ghany","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"277","DOI":"10.4254\/wjh.v12.i6.277","article-title":"Changing delta hepatitis patient profile: A single center experience in Valencia region, Spain","volume":"12","author":"Berenguer","year":"2020","journal-title":"World J. Hepatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jhep.2020.07.042","article-title":"Impact of COVID-19 on global HCV elimination efforts","volume":"74","author":"Blach","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S2468-1253(20)30238-7","article-title":"The impact of COVID-19 on hepatitis elimination","volume":"5","author":"Wingrove","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/liv.14833","article-title":"Is hepatitis delta underestimated?","volume":"41","author":"Papatheodoridi","year":"2021","journal-title":"Liver Int."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/liv.14357","article-title":"New epidemiology of hepatitis delta","volume":"40","author":"Vlachogiannakos","year":"2020","journal-title":"Liver Int."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/jvh.13899","article-title":"Epidemiology of hepatitis D virus infection in Europe: Is it vanishing?","volume":"31","author":"Demirel","year":"2024","journal-title":"J. Viral Hepat."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/apt.18227","article-title":"Enhancing linkage to care for hepatitis B, D, and C patients: A retrospective-prospective study","volume":"60","author":"Palom","year":"2024","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Lotto, M., Ramier, C., Carrat, F., P\u00e9ri\u00e8res, L., Delaroque-Astagneau, E., Nicol, J., Marcellin, F., Zoulim, F., Di Beo, V., and Bertheau, M. (2025). Mortality risk in migrant and non-migrant individuals with chronic hepatitis B virus infection: A French hospital-based cohort study (ANRS CO22 HEPATHER). BMC Glob. Public Health, 3.","DOI":"10.1186\/s44263-025-00173-7"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.eimc.2018.04.002","article-title":"Hepatitis C prevalence among the migrant population in Spain: A systematic review and meta-analysis","volume":"37","author":"Lazarus","year":"2019","journal-title":"Enferm. Infecc. Microbiol. Clin."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e00168","DOI":"10.1097\/HC9.0000000000000168","article-title":"Advancing research, awareness, screening, and linkage to care to eliminate HDV in the U.S","volume":"7","author":"Glynn","year":"2023","journal-title":"Hepatol. Commun."},{"key":"ref_28","unstructured":"(2026, January 02). World Hepatitis Alliance. Available online: https:\/\/www.worldhepatitisalliance.org\/news\/global-survey-reveals-urgent-gaps-in-awareness-access-and-treatment-for-hepatitis-d."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"100307","DOI":"10.1016\/j.jmh.2025.100307","article-title":"Navigating healthcare pathways: Cascade of prevention and care for chronic viral hepatitis in asylum seekers and refugees. A multicenter analysis in Northern Italy","volume":"11","author":"Formenti","year":"2025","journal-title":"J. Migr. Health"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s43856-022-00077-9","article-title":"A cascade of care analysis on the elimination of hepatitis C from public hospitals in Madrid","volume":"21","author":"Lazarus","year":"2022","journal-title":"Commun. Med."},{"key":"ref_31","unstructured":"ECDC (2023). A Systematic Literature Review of Interventions to Increase Linkage to Care and Adherence to Treatment for Hepatitis B and C, HIV and Tuberculosis Among People Who Inject Drugs, ECDC. ECDC Technical Report."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/s43856-023-00420-8","article-title":"Community-based screening enhances hepatitis B virus linkage to care among West African migrants in Spain","volume":"3","author":"Picchio","year":"2023","journal-title":"Commun. Med."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Lens-Perol, G., V\u00e1zquez-Cancela, O., Santana-Armas, M., Bouzas-Rodriguez, A., Tu\u00f1ez-Bastida, V., Dom\u00ednguez-Lago, A., P\u00e9rez-Freixo, H., Peiteado-Romay, C., V\u00e1zquez-Lago, J.M., and Fern\u00e1ndez-P\u00e9rez, C. (2025). Serological Vulnerability and Active Infection Detection Among Recently Arrived Migrants in Spain: Results from a Targeted Screening Program. Trop. Med. Infect. Dis., 10.","DOI":"10.3390\/tropicalmed10060169"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ijid.2023.02.006","article-title":"Trends in chronic hepatitis B virus infection in Italy over a 10-year period: Clues from the nationwide PITER and MASTER cohorts toward elimination","volume":"129","author":"Brancaccio","year":"2023","journal-title":"Int. J. Infect. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e679","DOI":"10.1093\/infdis\/jiae023","article-title":"Growing Awareness: Limited Testing and Screening Bias for Hepatitis Delta Virus in Utah 2000-2021","volume":"230","author":"Hesterman","year":"2024","journal-title":"J. Infect. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/jvh.14005","article-title":"Perspectives of People Living with Chronic Hepatitis D: Impact of Disease and Unmet Needs Along the Care Cascade","volume":"31","author":"Zovich","year":"2024","journal-title":"J. Viral Hepat."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2500150","DOI":"10.2807\/1560-7917.ES.2025.30.29.2500150","article-title":"Prevalence and risk factors of active hepatitis C infection among at-risk migrant populations in Madrid, Spain, 2019 to 2023","volume":"30","author":"Ryan","year":"2025","journal-title":"Eurosurveillance"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1007\/s15010-022-01938-0","article-title":"Hepatitis D virus infection in a large cohort of immigrants in southern Italy: A multicenter, prospective study","volume":"50","author":"Pisaturo","year":"2022","journal-title":"Infection"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/18\/2\/174\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T05:13:48Z","timestamp":1769750028000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/18\/2\/174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,28]]},"references-count":38,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["v18020174"],"URL":"https:\/\/doi.org\/10.3390\/v18020174","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,28]]}}}